April 17, 2024
Beckley Psytech’s Phase I study results of novel 5-MeO-DMT formulation BPL-003 published in The Journal of Psychopharmacology
BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally. The Phase I, placebo-controlled, single ascending dose study was completed in November 2022 and explored the safety, tolerability, pharmacokinetics, and pharmacodynamics of BPL-003 alongside psychological support in healthy participants. BPL-003 was shown to be safe and well-tolerated in the study with a predictable pharmacokinetic profile and a reliable induction of psychedelic experiences with single doses of up to 12 mg in healthy participants. Psychedelic experiences correlated to 5-MeO-DMT exposure and had a rapid onset and short duration, with consciousness-altering effects resolving in less than 2 hours.
Read more